United Kingdom (UK)
Recombinant monoclonal antibody to Nicotine. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma NIC9D9.
Alternative Name(s) of Target: Nicotin; rac-3-(1-methylpyrrolidin-2-yl)pyridine; CAS: 54-11-5; CHEBI:18723; Nic12; 9D9
Immunogen: The original antibody was generated by immunizing mice with keyhole limpet hemocyanin (KLH) conjugated nicotine hapten.
Specificity: This antibody is highly specific for S-(–)-nicotine. Nicotine is a plant alkaloid, found in the tobacco plant and other plants of the nightshade family. It is an addictive central nervous system (CNS) stimulant that causes either ganglionic stimulation in low doses or ganglionic blockage in high doses. It is the main psychoactive ingredient in tobacco products and a major component of cigarettes, which is also is used therapeutically to help with smoking cessation and reduce withdrawal symptoms.
Application Notes: The binding characterization of this antibody to nicotine-BSA hapten was done using ELISA (PMID: 11397142). A study to determine the effect of vaccination with this antibody towards a series of nicotine challenges and testing sessions was conducted. Passive immunization with NIC9D9 resulted in a 66.9% decrease in locomotor activity versus a 3.4% decrease in controls (PMID: 14738965). This antibody was also used in the generation of an adeno-associated virus (AAV) gene transfer vector which persistently expresses this antibody in vivo and prevents nicotine from reaching its receptors in the brain. This vector is called AAVantiNic and it generates an antibody similar to Nic9D9 that binds nicotine with an affinity of Kd= 43 nM. The mice treated with this vector showed 7 times greater amounts of nicotine in the serum of which 83% was bound to IgG. The vector blocked nicotine-mediated alterations in arterial blood pressure, heart rate and locomotor activity (PMID: 22745437).
Antibody first published in:
Carrera et al. Investigations using immunization to attenuate the psychoactive effects of nicotine. Bioorg Med Chem. 2004 Feb 1;12(3):563-70. PMID:14738965
Note on publication:
The paper describes the use of this antibody in the immunopharmacotherapy for treating nicotine addiction.